Oncoinfo· @Oncoinfo_it · X·· 13 小时前评分70
正文 · 原文
#ESMO26 | Izalontamab brengitecan nel carcinoma avanzato recidivante o metastatico HR+/HER- pre-trattato: l'efficacia di questo nuovo ADC è chiara, ma il vero interrogativo è un altro... 🤔
Armando Orlandi su PANKU-Breast01👇
#OncoSTEPS #metastaticbreastcancer #mBC #ADCs
18 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA50按 Proffered paper 1: Breast cancer, early and advanced stage 对上
PANKU-Breast01: Randomized phase III study of izalontamab brengitecan (iza-bren) in previously treated unresectable locally advanced or metastatic (LA/M) hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC)
https://esmocongress.esmo.org来源：Oncoinfo · x.com